Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    There’s a Decent Black Friday Sale on New and Refurbished reMarkable Digital Notebooks

    November 27, 2025

    Forget B2B or B2C: It’s time for B2H

    November 27, 2025

    AAVE Price Prediction: Recovery to $208-$246 Expected Within 4 Weeks as Oversold Conditions Signal Bounce

    November 26, 2025
    Facebook X (Twitter) Instagram
    Trending
    • There’s a Decent Black Friday Sale on New and Refurbished reMarkable Digital Notebooks
    • Forget B2B or B2C: It’s time for B2H
    • AAVE Price Prediction: Recovery to $208-$246 Expected Within 4 Weeks as Oversold Conditions Signal Bounce
    • 10 exercises to improve posture and mobility if you sit all day
    • Vaccine Skeptic Given Leadership Job At CDC
    • How Zcash Became Coinbase’s Most-Searched Crypto in November
    • Practical, Refined Picks He’ll Actually Use · Primer
    • ByHeart Baby Formula From All Lots May Be Contaminated With Botulism Bacteria, Tests Show
    Facebook X (Twitter)
    SBM Global News
    Demo
    • Home
    • Top Stories
      • Politics
    • Business
      • Small Business
      • Marketing
    • Finance
      • Investment
    • Technology

      Character.AI will offer interactive ‘Stories’ to kids instead of open-ended chat

      November 26, 2025
      Read More

      Doomshell Software – Company Profile

      November 25, 2025
      Read More

      Roblox CEO interview gets heated over child safety

      November 24, 2025
      Read More

      Monarch Tractor preps for layoffs and warns employees it may ‘shut down’

      November 20, 2025
      Read More

      StratEngine AI – Company Profile

      November 20, 2025
      Read More
    • Lifestyle
      • Travel
    • Feel Good
    • Get In Touch
    SBM Global News
    Demo
    Home»Health»What The Mifepristone Case Means For Reproductive Health
    Health

    What The Mifepristone Case Means For Reproductive Health

    By Staff WriterDecember 20, 20246 Mins Read
    Facebook Twitter LinkedIn Reddit Email
    #image_title
    Share
    Facebook Twitter LinkedIn Pinterest Email

    A drug approved by the FDA over two decades ago for use in medical abortions and miscarriages is at risk of being pulled from the market after a decision by a Trump-appointed federal judge in Texas on Friday.

    However, a second federal judge in Washington state issued a competing ruling that would prohibit the FDA from pulling the drug, mifepristone, off the market, in the 12 states covered by the ruling, which include Washington, Oregon, Arizona, Colorado, New Mexico, and Vermont.

    The conflicting rulings may set the stage for a Supreme Court battle over the drug, which is used in combination with misoprostol for medical abortions and to treat miscarriages.

    In the Texas ruling, US District Judge Matthew Kacsmaryk said the FDA did not consider “the psychological effects of the drug or an evaluation of the longterm medical consequences of the drug.” His decision is on hold for seven days, giving the Biden administration time to appeal — which it has already done. On Friday night, the Department of Justice filed an appeal in the Texas case, and issued a statement saying it “strongly disagrees” with the ruling. The DOJ will also review the Washington ruling.

    As of April 8, mifepristone is still available in the United States. Depending on the ultimate decision, it could mean that mifepristone, which is widely considered safe by medical experts, may not be able to be dispensed even in states where abortion is legal. 

    The medical community is in consensus that mifepristone, which was first approved in 2000, is safe under its current regulations. The American College of Obstetricians and Gynecologists, American Medical Association, Society for Maternal-Fetal Medicine, and nine other medical organizations submitted a brief to the US District Court for the Northern District of Texas, Amarillo Division, saying there is “overwhelming evidence demonstrating that mifepristone — which has undergone rigorous testing and review and has been safely used in the United States for 23 years — is conclusively safe and effective.” 

    Coming on the heels of last year’s overturn of Roe v. Wade, the Texas ruling, which major medical groups said is not based on science, would place further burdens on equal access to reproductive healthcare, including abortion treatment. A Christian legal group filed the lawsuit claiming, among other things, that mifepristone is a dangerous drug and the FDA has “failed America’s women and girls.”

    The lawsuit is the latest step in a long-running effort to restrict or even ban abortion across the United States. Following the Supreme Court’s overturn of Roe, many states rushed to ban or seriously restrict abortion.

    As of April 2023, 13 states have banned abortion from the point of conception, according to reproductive rights think tank the Guttmacher Institute, and many states with restrictions are also looking to tighten them: State lawmakers in Florida, for example, recently introduced bills to change the deadline to access abortion from 15 weeks to 6 weeks, before many people know they’re pregnant. Notably, many of the new laws restricting abortion exclude the pregnant person from prosecution for their own abortion — making self-managed abortion via medication a vital lifeline. Medical abortions currently account for 53% of abortions in the US. 

    Even if the courts ultimately rule in favor of blocking access to the drug, doctors will continue to make evidence-based abortion options available to their patients in states where it’s legal, healthcare providers said.

    “When my patients and I come up with a treatment plan together, my priority is to use the science to make recommendations that best honors my patients’ priorities, and for a third party to interfere with that process because of their own interests is ridiculous,” said Dr. Melissa Myo, an OB-GYN in California and fellow of the advocacy group Physicians for Reproductive Health. “Yes, we will continue to have alternatives because our goal is to take care of our patients, but it also means that patients will have a more narrow range of choices available to them, for no justifiable reason.”

    What are the abortion options if mifepristone is no longer available?

    First, here’s a brief explanation of how mifepristone works: Used through the 10th week of pregnancy, the drug stops the production of progesterone, which is necessary for pregnancy to continue; then, misoprostol is given to expel the pregnancy tissue from the uterus, which involves cramping and bleeding. 

    The two-drug regimen is the recognized standard of care for medication abortion, with less than 1% of patients having any serious side effects, as ACOG stated in the court brief. There is a greater risk of complications and death from colonoscopy, wisdom tooth removal, or using Viagra. 

    Both drugs together are also used for miscarriage treatment, particularly for “missed abortions,” which are miscarriages where the pregnancy has stopped progressing but the tissue has not been expelled by the body. Failure to remove the fetal tissue in these cases can lead to infections and potentially life-threatening sepsis.

    Demo

    “Mifepristone is a very safe and effective medication that millions of patients have used for medication abortion and miscarriage management,” said Dr. Kristyn Brandi, a fellow of the American College of Obstetricians and Gynecologists.

    If access to mifepristone is restricted nationwide, there are two alternatives. 

    One option is using misoprostol alone. “Prior to the approval of mifepristone, a regimen that only uses misoprostol was used and has been shown to be safe and effective,” Myo said. “Misoprostol-only regimens are used worldwide in places that do not have mifepristone.” With the single-drug method, “multiple doses of misoprostol are taken to induce contractions so that the uterus can pass the pregnancy,” she said.

    However, “the addition of mifepristone decreases the amount of misoprostol and time required to completely pass the pregnancy,” Myo said. “While misoprostol-only regimens are also safe and effective, banning mifepristone when we have good evidence that tells us it is safe is another way for politics to dictate quality medical care.” 

    Brandi said that although using misoprostol alone is an option, it may not be the best one. “There are other options for medication abortion, but the data show that mifepristone plus misoprostol is the safest and most effective treatment regimen,” she said. Neither the evidence supporting the use of mifepristone nor the clinical recommendations from ACOG have changed — only the law has.

    Misoprostol can also be used on its own for miscarriage management, but, as with elective abortion, research has shown that adding mifepristone for miscarriage treatment is more effective.



    View original article here

    Share. Facebook Twitter LinkedIn Email Reddit
    Previous ArticleThe Grinch That Stole Creativity: 2024 in Seussian Review
    Next Article Dr Dre Slams Rep. Marjorie Taylor Greene For Using His Music

    Related Posts

    ByHeart Baby Formula From All Lots May Be Contaminated With Botulism Bacteria, Tests Show

    November 26, 2025
    Read More

    22 Small Things That People Say Made Them Drastically Happier

    November 25, 2025
    Read More

    The Bril UV Toothbrush Sanitizer Can Help Your Oral Hygiene

    November 21, 2025
    Read More
    Add A Comment

    Leave A Reply Cancel Reply

    Demo
    Top Posts

    Former FBI, CIA Head Has ‘Serious Concerns’ With Trump Cabinet Picks

    December 28, 2024363

    How To Find Unclaimed Money From The Government

    October 4, 2025122

    Tezos (XTZ) Shows Mixed Signals at $0.78 as Bulls Fight for Control

    September 19, 2025100

    How to Use ChatGPT to Discover Hidden Crypto Gems

    October 12, 202598
    Don't Miss
    Lifestyle

    There’s a Decent Black Friday Sale on New and Refurbished reMarkable Digital Notebooks

    By Staff WriterNovember 27, 20254 Mins Read

    We may earn a commission from links on this page. Deal pricing and availability subject…

    Read More

    Forget B2B or B2C: It’s time for B2H

    November 27, 2025

    AAVE Price Prediction: Recovery to $208-$246 Expected Within 4 Weeks as Oversold Conditions Signal Bounce

    November 26, 2025

    10 exercises to improve posture and mobility if you sit all day

    November 26, 2025
    Stay In Touch
    • Facebook
    • Twitter
    Demo
    About Us

    Small Business Minder brings together business and related news from around the world in one place. Follow us for all the business news you'll need.

    Facebook X (Twitter)
    Our Picks

    There’s a Decent Black Friday Sale on New and Refurbished reMarkable Digital Notebooks

    November 27, 2025

    Forget B2B or B2C: It’s time for B2H

    November 27, 2025
    Most Popular

    Former FBI, CIA Head Has ‘Serious Concerns’ With Trump Cabinet Picks

    December 28, 2024363

    How To Find Unclaimed Money From The Government

    October 4, 2025122
    © 2025 Small Business Minder
    • Home
    • Get In Touch

    Type above and press Enter to search. Press Esc to cancel.

    Ad Blocker Enabled!
    Ad Blocker Enabled!
    Our website is made possible by displaying online advertisements to our visitors. To get the most from our site, please disable your Ad Blocker.